Risk Factor Adapted Treatment of Hodgkin’s Lymphoma in Childhood: Strategies and Results of Three Consecutive Multicenter Studies in the Federal Republic of Germany

Schellong, G; Hörnig, I.; Schwarze, E. W.; Wannenmacher, M

doi:10.1007/978-3-642-83781-4_22

Cited by 13 publications

(5 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, Faría et al published a small series of patients from Brazil treated for Hodgkin disease with an OS estimate of 0.78 [35]. They mentioned that these results were lower than developed countries data [2,4,19], but similar to other underdeveloped countries [32,[36][37][38]. Our results are more comparable to those of developed nations.…”

Section: Discussionsupporting

confidence: 73%

“…The five-year survival for children and adolescents with Hodgkin disease is approximately 90% nowadays [1][2][3][4][5]. We had previously demonstrated that survival in childhood Hodgkin disease experienced a rather marked improvement during the last decades in Argentina [17].…”

Section: Discussionmentioning

confidence: 99%

“…Hodgkin disease is the childhood malignancy with current highest cure rate. Five-year survival in children and adolescents is approximately 90% [1][2][3][4][5]. Thus, since it seems almost impossible to increase survival substantially, major efforts have been made to reduce late sequel induced by treatment (i.e.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Hodgkin disease in children: Results of a prospective randomized trial in a single institution in Argentina

Sackmann‐Muriel¹,

Zubizarreta²,

Gallo³

et al. 1997

Med. Pediatr. Oncol.

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 73%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Hodgkin disease in children: Results of a prospective randomized trial in a single institution in Argentina

Sackmann‐Muriel¹,

Zubizarreta²,

Gallo³

et al. 1997

Med. Pediatr. Oncol.

View full text Add to dashboard Cite

“…They mentioned that these results were lower than developed countries data [2,4,19], but similar to other underdeveloped countries [32,[36][37][38]. Our results are more comparable to those of developed nations.…”

Section: Discussionsupporting

confidence: 74%

Hodgkin disease in children: Results of a prospective randomized trial in a single institution in Argentina

Sackmann‐Muriel

Zubizarreta

Gallo

et al. 1997

Med. Pediatr. Oncol.

View full text Add to dashboard Cite

Purpose To compare prospective treatment strategies in childhood Hodgkin disease to the following subsets of patients: a) Favorable prognostic group: these patients were randomized to receive 6 vs. 3 CVPP chemotherapy cycles without radiotherapy (CVPP: cyclophosphamide, vinblastine, procarbazine, and prednisone. The scheme was repeated every 28 days). b) Intermediate prognostic group: these patients were randomized to receive 6 cycles of CVPP or AOPE (AOPE: Adriamycin, vincristine, prednisone, and etoposide). Between the third and fourth cycles, all patients in this group received radiotherapy (RT)(30–40 Gy to initially involved areas). c) Unfavorable prognostic group: those patients received a single arm regimen of 6 cycles of CCOPP/CAPTe (3 of each combination) every 28 days. All these patients received radiotherapy (30–40 Gy to initially involved areas). Results From October 1987 to December 1994, a total of 114 children and adolescents were evaluated. Mean age was 9 (range 2–17) years. There were 72 boys and 42 girls. With a median follow‐up of 5 (range 1.5–8.7) years, at 80 months event‐free survival (EFS) and overall survival (OS) for the whole cohort are 0.809 (SE: 0.04) and 0.873 (SE: 0.04), respectively (SE: Standard Error). Favorable prognostic group (n = 26) EFS is 0.831 (0.09) (Arm CVPP × 3: 0.857 (0.13) and Arm CVPP × 6: 0.875 (0.08); p = non significant). Intermediate prognostic group (n = 64) EFS is 0.806 (0.05) (Arm CVPP × 6 + RT: 0.872 (0.05) and Arm AOPE × 6 + RT: 0.667 (0.10); p = 0.04). Unfavorable group (n = 24) EFS is 0.829 (0.07). Conclusions Results of treatment for the whole group are satisfactory. However, 3 cycles of CVPP without radiotherapy obtain equal EFS than 6 cycles without radiotherapy in the favorable prognostic group. In the intermediate prognostic group, 6 cycles of CVPP plus radiotherapy obtain a superior EFS than 6 cycles of AOPE plus radiotherapy. With the success of treatment for Hodgkin disease in children, future research needs to be focused in reducing toxicity without altering the excellent actual outcome. Med. Pediatr. Oncol. 29:544–552, 1997. © 1997 Wiley‐Liss, Inc.

show abstract

“…COPP) that substituted less leukemogenicand gonadotoxic alkylating agents (e.g., cyclophosphamide) for mechlorethamine or alternated ABVD to reduce cumulative alkylating agent dose exposure. 56–58 The antineoplastic activity of ABVD proved to be superior to MOPP, 59 but was associated with cardiopulmonary toxicity related to doxorubicin and bleomycin. 60 …”

Section: Hodgkin Lymphomamentioning

confidence: 99%

Lessons from the past: Opportunities to improve childhood cancer survivor care through outcomes investigations of historical therapeutic approaches for pediatric hematological malignancies

Hudson

Neglia

Woods

et al. 2011

Pediatric Blood & Cancer

121

134

View full text Add to dashboard Cite

Investigations of long-term outcomes have been instrumental in designing safer and more effective contemporary therapies for pediatric hematological malignancies. Despite the significant therapeutic changes that have occurred over the last five decades, therapy modifications largely represent refinements of treatment protocols using agents and modalities that have been available for more than 30 years. This review summarizes major trends in the evolution of treatment of pediatric hematological malignancies since 1960 to support the relevance of the study of late effects of historical therapeutic approaches to the design and evaluation of contemporary treatment protocols and the follow-up of present-day survivors.

show abstract

Risk Factor Adapted Treatment of Hodgkin’s Lymphoma in Childhood: Strategies and Results of Three Consecutive Multicenter Studies in the Federal Republic of Germany

Cited by 13 publications

References 7 publications

Hodgkin disease in children: Results of a prospective randomized trial in a single institution in Argentina

Hodgkin disease in children: Results of a prospective randomized trial in a single institution in Argentina

Hodgkin disease in children: Results of a prospective randomized trial in a single institution in Argentina

Lessons from the past: Opportunities to improve childhood cancer survivor care through outcomes investigations of historical therapeutic approaches for pediatric hematological malignancies

Contact Info

Product

Resources

About